Mary Jane Hogan

Mary Jane Hogan, MD, MPH, is an Associate Professor of Pediatrics (Hematology/Oncology) at Yale School of Medicine. She specializes in pediatric blood disorders, including non-malignant hematologic conditions and cancers like leukemia and lymphoma. Dr. Hogan’s research focuses on improving outcomes for children with blood disorders through advancements in gene therapy, diagnostic strategies, and long-term survivorship care.

Education:

• MD, University of Connecticut School of Medicine (1990)
• MPH, Johns Hopkins University Bloomberg School of Public Health (2010)
• Residency in Pediatrics, University of Chicago Children’s Hospital (1993)
• Fellowships in Pediatric Hematology/Oncology at University of Chicago Children’s Hospital (1994–1998)

Research Interests: Dr. Hogan’s work emphasizes gene therapy for genetic blood disorders, late toxicities of hematopoietic cell transplantation (HCT), and optimizing care for pediatric cancer survivors. She collaborates on clinical trials involving novel therapies for hemophilia and sickle cell disease. Her recent publications highlight advancements in diagnostic approaches for soft tissue sarcomas, spinal tumors, and neurocognitive outcomes in cancer survivors.

Publications Trends: Her articles focus on translational therapies (e.g., lentiviral gene therapy for adrenoleukodystrophy), diagnostic challenges in pediatric oncology, and managing treatment-related complications like tumor lysis syndrome. Recent work also addresses quality-of-life issues for childhood cancer survivors.

Awards:

• Make A Wish Foundation Honoree (2003)
• Pediatrics Post-Doctoral Research Day Award (University of Chicago, 1996 & 1997)

Grants & Trials: Sub-investigator on clinical trials evaluating gene-edited stem cells for sickle cell disease, immunotherapy combinations for lymphoma, and targeted therapies for gliomas. She leads efforts to improve access to cutting-edge treatments through the Children’s Oncology Group.

Labs & Teams: Collaborates with the Yale Cancer Center and the Pediatric Hematology/Oncology Program to advance multidisciplinary care. Engaged in translational research to bridge laboratory discoveries with clinical practice.